文献速递肝病

尿中性粒细胞明胶酶相关脂质运载蛋白在肝硬化合并急性肾损伤患者中的诊断与预后价值

Diagnostic and prognostic performance of urinary neutrophil gelatinase-associated lipocalin in patients with cirrhosis and acute kidney injury.
PubMed 文献 · Hepatology · 2023-04-17

该研究纳入162例肝硬化合并急性肾损伤(AKI)患者,评估尿中性粒细胞明胶酶相关脂质运载蛋白(uNGAL)在鉴别AKI病因、预测特利加压素联合白蛋白治疗HRS-AKI反应及预测院内死亡中的作用。uNGAL预测ATN-AKI的AUC为0.854,阈值220 ng/ml时敏感度89%、特异度78%,且该阈值独立关联无应答风险(aOR 6.17)及院内死亡(aOR 1.74)。

要点

  • uNGAL在ATN-AKI患者中均值1162 ng/ml,显著高于其他类型AKI的109 ng/ml(p<0.001)。
  • uNGAL预测ATN-AKI的AUC为0.854,最佳阈值220 ng/ml(敏感度89%,特异度78%)。
  • 阈值220 ng/ml独立关联HRS-AKI对特利加压素联合白蛋白无应答(aOR 6.17)及院内死亡(aOR 1.74)。

核心结论

  • uNGAL是肝硬化AKI病因鉴别诊断的 adequate 生物标志物,可预测HRS-AKI对特利加压素联合白蛋白的应答,并为院内死亡的独立预测因子。

研究设计与样本

  • 研究连续纳入2015年至2020年162例肝硬化合并AKI患者,随访至移植、死亡或90天。
  • 检测标准尿液标志物及uNGAL,收集AKI治疗、类型及缓解数据。

主要发现

  • 35例(21.6%)为肾前性AKI,64例(39.5%)为HRS-AKI,27例(16.7%)为ATN-AKI,36例(22.2%)为混合型AKI。
  • ATN-AKI患者uNGAL均值1162 ng/ml(95%CI 423-2105 ng/ml),其他类型AKI为109 ng/ml(95%CI 52-192 ng/ml),差异有统计学意义(p<0.001)。
  • uNGAL预测ATN-AKI的AUC为0.854(95%CI 0.767-0.941,p<0.001),最佳阈值220 ng/ml,敏感度89%,特异度78%。
  • 阈值220 ng/ml独立关联无应答风险升高(aOR 6.17,95%CI 1.41-27.03,p=0.016)。
  • 多变量分析(校正年龄、MELD、慢加急性肝衰竭、白细胞及AKI类型)显示uNGAL为院内死亡的独立预测因子(aOR 1.74,95%CI 1.26-2.38,p=0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Acute kidney injury (AKI) commonly occurs in patients with decompensated cirrhosis. Urinary neutrophil gelatinase-associated lipocalin (uNGAL) could help discriminate between different etiologies of AKI. The aim of this study was to investigate the use of uNGAL in (1) the differential diagnosis of AKI, (2) predicting the response to terlipressin and albumin in patients with hepatorenal syndrome-AKI (HRS-AKI), and (3) predicting in-hospital mortality in patients with AKI. APPROACH AND RESULTS: One hundred sixty-two consecutive patients with cirrhosis and AKI were included from 2015 to 2020 and followed until transplant, death, or 90 days. Standard urinary markers and uNGAL were measured. Data on treatment, type, and resolution of AKI were collected. Thirty-five patients (21.6%) had prerenal AKI, 64 (39.5%) HRS-AKI, 27 (16.7%) acute tubular necrosis-AKI (ATN-AKI), and 36 (22.2%) a mixed form of AKI. Mean values of uNGAL were significantly higher in ATN-AKI than in other types of AKI (1162 ng/ml [95% CI 423-2105 ng/ml] vs. 109 ng/ml [95% CI 52-192 ng/ml]; p < 0.001). uNGAL showed a high discrimination ability in predicting ATN-AKI (area under the receiver operating characteristic curve, 0.854; 95% CI 0.767-0.941; p < 0.001). The best-performing threshold was found to be 220 ng/ml (sensitivity, 89%; specificity, 78%). The same threshold was independently associated with a higher risk of nonresponse (adjusted OR [aOR], 6.17; 95% CI 1.41-27.03; p = 0.016). In multivariable analysis (adjusted for age, Model for End-Stage Liver Disease, acute-on-chronic liver failure, leukocytes, and type of AKI), uNGAL was an independent predictor of in-hospital mortality (aOR, 1.74; 95% CI 1.26-2.38; p = 0.001). CONCLUSIONS: uNGAL is an adequate biomarker for making a differential diagnosis of AKI in cirrhosis and predicting the response to terlipressin and albumin in patients with HRS-AKI. In addition, it is an independent predictor of in-hospital mortality.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Gambino C, Piano S, Stenico M, et al. Diagnostic and prognostic performance of urinary neutrophil gelatinase-associated lipocalin in patients with cirrhosis and acute kidney injury. Hepatology. 2023. PMID: 36125403. doi:10.1002/hep.32799

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。